Autologous Cells Derived Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of autologous anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.